Claritev Corp (CTEV) Financial Statements
Claritev Corp (CTEV) reported trailing twelve-month revenue of $994.7M (up 6.3% year on year) and net income of -$283.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$17.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTEVClaritev CorpFollow CTEV — free
—
Price chart with a free account
- Market cap
- 398.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.94 | 1.12 | 1.08 | 0.96 | 0.93 | 0.97 | 0.99 | |
| Gross profit | 0.62 | 0.94 | 0.88 | 0.73 | 0.69 | 0.71 | 0.73 | |
| Operating income | -0.13 | 0.39 | -0.36 | 0.16 | -1.39 | 0.03 | 0.03 | |
| Pre-tax income | 0.14 | 0.14 | -0.56 | -0.11 | -1.77 | -0.37 | -0.37 | |
| Income tax | 0.03 | 0.03 | 0.01 | -0.02 | -0.12 | -0.09 | -0.09 | |
| Net income | -0.52 | 0.10 | -0.57 | -0.09 | -1.65 | -0.28 | -0.28 | |
| Diluted EPS ($) | -1.11 | 0.16 | -0.90 | -5.69 | -101.92 | -17.30 | -17.01 | |
| Diluted shares (bn) | — | 0.652 | 0.639 | 0.016 | 0.016 | 0.016 | — |
USD billions · SEC XBRL
Claritev Corp — questions
- What is Claritev Corp's revenue?
- $994.7M over the twelve months to 2026-06-30, up 6.3% year on year, from its 10-Q and 10-K filings.
- What is Claritev Corp's net income?
- -$283.1M over the twelve months to 2026-06-30.
- What is Claritev Corp's free cash flow?
- -$17.9M over the twelve months to 2026-06-30.
- What are Claritev Corp's diluted earnings per share?
- $-17.01 over the twelve months to 2026-06-30.
Every figure on this page comes from Claritev Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.